How I treat paroxysmal nocturnal hemoglobinuria

Blood

Volumn 113, Issue 26, 2009, Pages 6522-6527

  Brodsky, Robert A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN; CORTICOSTEROID; ECULIZUMAB; FOLIC ACID; HEPARIN; IRON; ANTICOAGULANT AGENT; BACTERIAL VACCINE; COMPLEMENT COMPONENT C5; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; PHOSPHATIDYLINOSITOL GLYCAN CLASS A PROTEIN; PHOSPHATIDYLINOSITOL GLYCAN-CLASS A PROTEIN;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANTICOAGULATION; CLINICAL FEATURE; CLINICAL TRIAL; DRUG INDUCED HEADACHE; ERYTHROCYTE TRANSFUSION; GENE MUTATION; GRAFT VERSUS HOST REACTION; HEMOLYSIS; HEMOLYTIC ANEMIA; HUMAN; INTRAVASCULAR HEMOLYSIS; NEISSERIACEAE INFECTION; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATIENT MONITORING; PREGNANT WOMAN; PRIORITY JOURNAL; QUALITY OF LIFE; REFRACTORY ANEMIA; RETICULOCYTE COUNT; REVIEW; RISK REDUCTION; THROMBOSIS; TREATMENT INDICATION; ARTICLE; BLOOD TRANSFUSION; BONE MARROW; BONE MARROW TRANSPLANTATION; CELL CLONE; COMPLEMENT ACTIVATION; DISEASE MANAGEMENT; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENETICS; IMMUNOLOGY; MALE; MULTIMODALITY CANCER THERAPY; NEISSERIA; NEWBORN; PATHOLOGY; PREGNANCY; PREGNANCY COMPLICATION;

ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; BACTERIAL VACCINES; BLOOD TRANSFUSION; BONE MARROW; BONE MARROW TRANSPLANTATION; CLONE CELLS; COMBINED MODALITY THERAPY; COMPLEMENT ACTIVATION; COMPLEMENT C5; DISEASE MANAGEMENT; FEMALE; FOLIC ACID; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; INFANT, NEWBORN; IRON; MALE; MEMBRANE PROTEINS; NEISSERIA; NEISSERIACEAE INFECTIONS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; THROMBOSIS;

EID: 69249221393     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-03-195966     Document Type: Review

References (54)

1. Brodsky RA. Narrative review. Paroxysmal nocturnal hemoglobinuria: the physiology of complement-related hemolytic anemia. Ann Intern Med. 2008;148:587-595.
2. Parker CJ. Historical aspects of paroxysmal nocturnal haemoglobinuria: "defining the disease." Br J Haematol. 2002;117:3-22.
3. Parker C, Omine M, Richards S, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005;106:3699-3709. (Pubitemid 41739003)
4. Miyata T, Takeda J, Iida Y, et al. The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis. Science. 1993;259:1318-1320. (Pubitemid 23100269)
5. Miyata T, Yamada N, Iida Y, et al. Abnormalities of PIG-A transcripts in granulocytes from patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1994;330:249-255. (Pubitemid 24034137)
6. Medof ME, Kinoshita T, Nussenzweig V. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med. 1984; 160:1558-1578. (Pubitemid 15220783)
7. Rollins SA, Sims PJ. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. J Immunol. 1990;144:3478-3483.
8. Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA. 2005;293:1653-1662. (Pubitemid 40471796)
9. Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333:1253-1258.
10. de Latour RP, Mary JY, Salanoubat C, et al. Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood. 2008;112: 3099-3106.
11. Moyo VM, Mukhina GL, Garrett ES, Brodsky RA. Natural history of paroxysmal nocturnal hemoglobinuria using modern diagnostic assays. Br J Haematol. 2004;126:133-138.
12. Nishimura J, Kanakura Y, Ware RE, et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Baltimore). 2004;83: 193-207. (Pubitemid 38649949)
13. Mukhina GL, Buckley JT, Barber JP, Jones RJ, Brodsky RA. Multilineage glycosylphosphatidylinositol anchor deficient hematopoiesis in untreated aplastic anemia. Br J Haematol. 2001; 115:476-482.
14. Dunn DE, Tanawattanacharoen P, Boccuni P, et al. Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann Intern Med. 1999;131:401-408. (Pubitemid 29444429)
15. Wang H, Chuhjo T, Yamazaki H, et al. Relative increase of granulocytes with a paroxysmal nocturnal haemoglobinuria phenotype in aplastic anaemia patients: the high prevalence at diagnosis. Eur J Haematol. 2001;66:200-205. (Pubitemid 32324587)
16. + cells of patients with aplastic anaemia. Br J Haematol. 1995;91:245-252.
17. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006;108:2509-2519. (Pubitemid 44776983)
18. Nagarajan S, Brodsky RA, Young NS, Medof ME. Genetic defects underlying paroxysmal nocturnal hemoglobinuria that arises out of aplastic anemia. Blood. 1995;86:4656-4661.
19. Ham T. Chronic hemolytic anemia with paroxysmal nocturnal hemoglobinuria: a study of the mechanism of hemolysisin relation to acid-base equilibrium. N Engl J Med. 1937;217:915-917.
20. Hartmann RC, Jenkins DE. The "sugar-water" test for paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1966;275:155-157.
21. Rosse WF, Dacie JV. Immune lysis of normal human and paroxysmal nocturnal hemoglobinuria (PNH) red blood cells: I. The sensitivity of PNH red cells to lysis by complement and specific antibody. J Clin Invest. 1966;45:736-748.
22. Bessler M, Fehr J. Fc III receptors (FcRIII) on granulocytes: a specific and sensitive diagnostic test for paroxysmal nocturnal hemoglobinuria (PNH). Eur J Haematol. 1991;47:179-184.
23. Hall SE, Rosse WF. The use of monoclonal antibodies and flow cytometry in the diagnosis of paroxysmal nocturnal hemoglobinuria. Blood. 1996; 87:5332-5340. (Pubitemid 26189877)
24. Telen MJ, Green AM. The Inab phenotype: characterization of the membrane protein and complement regulatory defect. Blood. 1989;74: 437-441.
25. Yamashina M, Ueda E, Kinoshita T, et al. Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1990;323:1184-1189. (Pubitemid 20347405)
26. Brodsky RA, Mukhina GL, Li S, et al. Improved detection and characterization of paroxysmal nocturnal hemoglobinuria using fluorescent aerolysin. Am J Clin Pathol. 2000;114:459-466. (Pubitemid 33049682)
27. Parker MW, van der Goot FG, Buckley JT. Aerolysin: the ins and outs of a model channel-forming toxin. Mol Microbiol. 1996;19:205-212.
28. Nelson KL, Raja SM, Buckley JT. The glycosylphosphatidylinositol-anchored surface glycoprotein Thy-1 is a receptor for the channelforming toxin aerolysin. J Biol Chem. 1997;272: 12170-12174. (Pubitemid 27202800)
29. Brodsky RA, Mukhina GL, Nelson KL, et al. Resistance of paroxysmal nocturnal hemoglobinuria cells to the glycosylphosphatidylinositol-binding toxin aerolysin. Blood. 1999;93:1749-1756. (Pubitemid 29102504)
30. Hu R, Mukhina GL, Piantadosi S, et al. PIG-A mutations in normal hematopoiesis. Blood. 2005; 105:3848-3854.
31. Araten DJ, Nafa K, Pakdeesuwan K, Luzzatto L. Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals. Proc Natl Acad Sci U S A. 1999;96:5209-5214. (Pubitemid 29214562)
32. Ware RE, Pickens CV, DeCastro CM, Howard TA. Circulating PIG-A mutant T lymphocytes in healthy adults and patients with bone marrow failure syndromes. Exp Hematol. 2001;29:1403-1409.
33. Traulsen A, Pacheco JM, Dingli D. On the origin of multiple mutant clones in paroxysmal nocturnal hemoglobinuria. Stem Cells. 2007;25:3081-3084. (Pubitemid 350294433)
34. Wang H, Chuhjo T, Yasue S, Omine M, Nakao S. Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome. Blood. 2002;100: 3897-3902. (Pubitemid 35396854)
35. Matsui WH, Brodsky RA, Smith BD, Borowitz MJ, Jones RJ. Quantitative analysis of bone marrow CD34 cells in aplastic anemia and hypoplastic myelodysplastic syndromes. Leukemia. 2006;20: 458-462.
36. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. 2007;25:1256-1264. (Pubitemid 350076509)
37. Brodsky RA. Paroxysmal nocturnal hemoglobinuria. In: Hoffman R, Benz EJ Jr, Shattil SJ, et al, eds. Hematology: Basic Principles and Practice. Philadelphia, PA: Churchill Livingstone; 2009: 385-394.
38. Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006; 355:1233-1243. (Pubitemid 44427447)
39. Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008; 111:1840-1847.
40. Hillmen P, Muus P, Duhrsen U, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007;110:4123-4128. (Pubitemid 350248472)
41. Brodsky RA, Jones RJ. Aplastic anaemia. Lancet. 2005;365:1647-1656.
42. Young NS. Acquired aplastic anemia. Ann Intern Med. 2002;136:534-546.
43. Risitano AM, Notaro R, Marando L, et al. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood. 2009;113:4094-4100.
44. Schubert J, Hillmen P, Roth A, et al. Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2008 May 22 [Epub ahead of print].
45. Saso R, Marsh J, Cevreska L, et al. Bone marrow transplants for paroxysmal nocturnal haemoglobinuria. Br J Haematol. 1999;104:392-396.
46. Perfault de Latour R, Schrezenmeier H, Mary JY, et al. Stem cell transplantation for paroxysmal nocturnal hemoglobinuria: an ongoing joint study of the AAWP EBMT group and the French Society of Hematology [abstract]. Blood. 2008;112:Abstract 1181.
47. Antin JH, Ginsburg D, Smith BR, et al. Bone marrow transplantation for paroxysmal nocturnal hemoglobinuria: eradication of the PNH clone and documentation of complete lymphohematopoietic engraftment. Blood. 1985;66:1247-1250.
48. Cho SG, Lim J, Kim Y, et al. Conditioning with high-dose cyclophosphamide may not be sufficient to provide a long-term remission of paroxysmal nocturnal hemoglobinuria following syngeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 2001;28:987-988.
49. Suenaga K, Kanda Y, Niiya H, et al. Successful application of nonmyeloablative transplantation for paroxysmal nocturnal hemoglobinuria. Exp Hematol. 2001;29:639-642. (Pubitemid 32463902)
50. Brodsky RA, Luznik L, Bolanos-Meade J, et al. Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases. Bone Marrow Transplant. 2008;42:523-527.
51. Kuo GP, Brodsky RA, Kim HS. Catheter-directed thrombolysis and thrombectomy for the Budd- Chiari syndrome in paroxysmal nocturnal hemoglobinuria in three patients. J Vasc Interv Radiol. 2006;17:383-387.
52. Hall C, Richards S, Hillmen P. Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood. 2003;102:3587-3591. (Pubitemid 37409375)
53. Ray JG, Burows RF, Ginsberg JS, Burrows EA. Paroxysmal nocturnal hemoglobinuria and the risk of venous thrombosis: review and recommendations for management of the pregnant and nonpregnant patient. Haemostasis. 2000;30:103-117.
54. Danilov AV, Smith H, Craigo S, et al. Paroxysmal nocturnal hemoglobinuria (PNH) and pregnancy in the era of eculizumab. Leuk Res. 2009;33:e4-e5.